GO
Loading...

Allergan Inc

More

  • *$46 bln offer from AbbVie rejected as undervaluing group. LONDON, June 23- Shire flagged the promise of existing and new drugs on Monday as evidence that AbbVie's $46 billion offer undervalued the company, the latest British firm to be targeted by a U.S. group seeking lower taxes.

  • Allergan rejects Valeant's takeover bid...again Monday, 23 Jun 2014 | 10:53 AM ET
    A doctor draws Allergan Inc. Botox into a syringe before administering it to a patient at the offices of Marcus Facial Plastic Surgery in Redondo Beach, California

    Allergan advised investors not to sell their shares to Valeant, which launched a hostile takeover offer for the Botox maker last week.

  • June 23- Allergan Inc on Monday advised investors not to sell their shares to Valeant Pharmaceuticals International which launched a hostile takeover offer for the California- based Botox maker last week, saying it was "grossly inadequate."

  • *$46 bln offer from AbbVie rejected as undervaluing group. LONDON, June 23- Shire flagged the promise of existing and new drugs on Monday as evidence that AbbVie's $46 billion offer undervalued the company, the latest British firm to be targeted by a U.S. group seeking lower taxes.

  • June 23- Allergan Inc on Monday advised investors not to sell their shares to Valeant Pharmaceuticals International which launched a hostile takeover offer for the California- based Botox maker last week, saying it was "grossly inadequate."

  • Aging stinks, so at least make some money from it Monday, 23 Jun 2014 | 8:00 AM ET

    The US population is getting grayer, and while getting old stinks, there are plenty of ways to profit from an aging demographic using ETFs.

  • *$46 bln offer from AbbVie rejected as undervaluing group. LONDON, June 23- Shire is to take a leaf out of AstraZeneca's playbook by giving long-range forecasts for its drugs as it seeks to convince shareholders that AbbVie's $46 billion offer undervalues the business.

  • *$46 bln offer from AbbVie rejected as undervaluing group. LONDON, June 23- Shire is to take a leaf out of AstraZeneca's playbook by giving long-range forecasts for its drugs as it seeks to convince shareholders that AbbVie's $46 billion offer undervalues the business.

  • *Shire rejects AbbVie offer valued at 46.26 pounds a share. LONDON, June 20- British drugmaker Shire has rejected a 27 billion-pound takeover offer from AbbVie, the latest attempt by a U.S. healthcare firm to tap into lower tax rates abroad via an acquisition.

  • LONDON, June 20- British drugmaker Shire has rejected a 27 billion-pound takeover offer from AbbVie, the latest attempt by a U.S. healthcare firm to tap into the London- listed group's low tax rate. Abbvie's takeover offer proposed creating a new U.S.-listed holding company with a UK tax domicile in a so-called "inversion" move.

  • June 18 (Reuters)- Valeant Pharmaceuticals Inc said on Wednesday it began an exchange offer for Botox maker Allergan Inc, taking its hostile $50.8 billion bid directly to shareholders.

  • Midday movers: Nokia, Walgreen, Yelp & More Wednesday, 18 Jun 2014 | 1:00 PM ET
    Traders on the floor of the New York Stock Exchange.

    Some of Wednesday's midday movers:

  • Legalize insider trading? That's ridiculous Wednesday, 18 Jun 2014 | 12:17 PM ET
    Billionaire Galleon Group hedge fund cofounder Raj Rajaratnam departs Manhattan Federal Court during his trial March 23, 2011 in New York City.

    One of the most breathtakingly incompetent ideas I've ever heard is the idea of legalizing all insider trading, says attorney Andrew Stoltmann.

  • UPDATE 1-Valeant says begins exchange offer for Allergan Wednesday, 18 Jun 2014 | 12:12 PM ET

    June 18- Valeant Pharmaceuticals Inc said on Wednesday it began an exchange offer for Allergan Inc, taking its $50.8 billion bid directly to shareholders. Valeant, which said on Tuesday it would launch the offer this week, said Allergan shareholders can choose to trade each share for $72 in cash and 0.83 Valeant shares.

  • Valeant says begins exchange offer for Allergan Wednesday, 18 Jun 2014 | 9:42 AM ET

    June 18- Valeant Pharmaceuticals Inc said on Wednesday it began an exchange offer for Allergan Inc that will expire on Aug. 15, unless extended.

  • It's time to legalize insider trading: Roth Tuesday, 17 Jun 2014 | 12:19 PM ET

    A new study reveals that insider trading is more rampant than previously thought; Carol Roth says it's time to legalize it.

  • Midday movers: Allergan, Coca-Cola, Netflix & More Tuesday, 17 Jun 2014 | 12:12 PM ET

    Some of Tuesday's midday movers:

  • June 17- Valeant Pharmaceuticals Inc said on Tuesday it will launch an exchange offer for Allergan Inc this week, allowing it to eventually take the unsolicited bid directly to shareholders.

  • Valeant officially goes hostile in bid for Allergan Tuesday, 17 Jun 2014 | 11:12 AM ET
    Botox by Allergan

    Valeant said it plans to launch an exchange offer to Allergan shareholders this week, soliciting proxies to call for a meeting to discuss its offer.

  • June 17- Valeant Pharmaceuticals Inc said on Tuesday it will launch an exchange offer for Allergan Inc this week, allowing it to eventually take the unsolicited bid directly to shareholders.